
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Sponsor : Orbis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Orbis and Vivtex Partner To Develop Oral nCycles Drugs
Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.
Product Name : nCycles
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Sponsor : Orbis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : AI Proteins
Deal Size : Undisclosed
Deal Type : Collaboration
Vivtex and AI Proteins Collaborate On Oral Biologic Therapies
Details : The collaboration aims to develop oral biologic therapies for inflammatory diseases, leveraging Vivtex’s GI-ORIS™ technology to enhance bioavailability of AI Proteins’ miniproteins.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : AI Proteins
Deal Size : Undisclosed
Deal Type : Collaboration
